Our Strategy

Our Strategy

The main pillar of the Company’s strategy is to build a broad portfolio of ANDA’s through Self Development, Collaborative Development and Business Development:

  • Self-Development using the strong product development platform built at the Suzhou facility and a high level of expertise through the PhDs resident in our NJ office (see Leadership Team for biographies of key personnel).
  • Collaborative Development to obtain access to development and manufacturing capabilities not present in Suzhou (see Media Room for publicly announced collaborations).
  • Business Development to gain access to products developed by third parties (see Media Room for publicly announced Business Development deals).

Our product focus is on solid oral dosage forms where limited competition may be expected, including:

  • First-to-market opportunities.
  • Products with development challenges (e.g. complex formulations – especially oral controlled release, bioequivalence challenges, etc.).
  • Products with manufacturing challenges (e.g. certain oncology products, DEA controlled substances, etc.).
  • Products requiring intellectual property challenges (e.g. Paragraph IV ANDA’s, Inter Partes Review petitions).

In the U.S., Amerigen sells its own labeled products directly to the large purchasers (distributors, pharmacies, retailers, GPO’s, etc.).

As the Company’s pipeline of filed and approved U.S. ANDA’s grows, an increasingly important part of the Company’s strategy is to leverage the capabilities and GMP standing of the Suzhou facility to bring high quality products from Amerigen’s ANDA portfolio into the China market where there is the potential to gain market share in an environment of increasing CFDA regulations. In addition, Amerigen has deals with U.S., European and Indian companies to bring their products into the China market.